FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are diverse tumors requiring molecular targets for new therapies.
• Forkhead box protein M1 (FOXM1) is a key transcription factor involved in cell proliferation and differentiation, implicated in various cancers.
• FOXM1's role in GEP-NENs, particularly its association with tumor characteristics and patient outcomes, remains to be fully elucidated.

Purpose of the Study:

• To investigate the association of FOXM1 with tumor differentiation and metastasis in gastrointestinal neuroendocrine neoplasms (GI-NENs).
• To evaluate the therapeutic potential of inhibiting FOXM1 in GEP-NEN cell lines.
• To determine if FOXM1 inhibition impacts GEP-NEN cell survival and synergizes with conventional chemotherapy.

Main Methods:

• Analysis of FOXM1 expression in relation to tumor differentiation and metastasis in GI-NENs.
• In vitro experiments using siomycin A, a FOXM1 inhibitor, on GEP-NEN cell lines.
• Assessment of siomycin A's effects on cell proliferation, mitosis, apoptosis, and synergy with chemotherapy.

Main Results:

• FOXM1 expression strongly correlates with tumor differentiation and the occurrence of metastases in GI-NENs.
• Inhibition of FOXM1 by siomycin A led to decreased mitosis and induced apoptosis in GEP-NEN cell lines.
• Siomycin A demonstrated synergistic effects when combined with chemotherapy and impaired GEP-NEN cell survival in vitro.

Conclusions:

• FOXM1 is significantly associated with clinical outcomes in GEP-NENs.
• Targeting FOXM1 represents a promising therapeutic strategy for GEP-NENs.
• FOXM1 inhibition warrants further investigation as a novel treatment approach for these tumors.